Search Results

You are looking at 131 - 140 of 149 items for :

  • "prostate-specific antigen" x
  • Refine by Access: All x
Clear All
Full access

Combined Androgen Blockade in Localized Prostate Cancer Treated With Definitive Radiation Therapy

Lucas K. Vitzthum, Chris Straka, Reith R. Sarkar, Rana McKay, J. Michael Randall, Ajay Sandhu, James D. Murphy, and Brent S. Rose

, cancer stage according to the 7th edition of the AJCC Cancer Staging Manual , Gleason score, and pretreatment prostate-specific antigen (PSA) were obtained from the tumor registry ( Table 1 ). Intermediate-risk disease was defined by stage T2b–c disease

Full access

Responsiveness to Resistance-Based Multimodal Exercise Among Men With Prostate Cancer Receiving Androgen Deprivation Therapy

Dennis R. Taaffe, Robert U. Newton, Nigel Spry, David J. Joseph, and Daniel A. Galvão

. Height and weight were assessed using a stadiometer and electronic scales, respectively, with body mass index (BMI; kg/m 2 ) calculated. Testosterone and prostate-specific antigen were measured at a commercial laboratory (PathWest Laboratory Medicine

Full access

Metastasis and Mortality in Men With Low- and Intermediate-Risk Prostate Cancer on Active Surveillance

P. Travis Courtney, Rishi Deka, Nikhil V. Kotha, Daniel R. Cherry, Mia A. Salans, Tyler J. Nelson, Abhishek Kumar, Elaine Luterstein, Anthony T. Yip, Vinit Nalawade, J. Kellogg Parsons, A. Karim Kader, Tyler F. Stewart, and Brent S. Rose

prostate-specific antigen (PSA) level <10 ng/mL. Intermediate-risk prostate cancer was defined as having ≥1 intermediate-risk feature (clinical tumor stage 2B–C, Gleason score 7, or PSA 10–20 ng/mL) and no high-risk or very-high-risk features (clinical

Full access

Androgen Deprivation Therapy and Risk of Cardiovascular Disease in Patients With Prostate Cancer Based on Existence of Cardiovascular Risk

Alice Dragomir, Nawar Touma, Jason Hu, Sylvie Perreault, and Armen G. Aprikian

data (eg, Gleason score, disease stage), and laboratory results (prostate-specific antigen level), were not measured. Despite accounting for other confounding variables through appropriate statistical methods using propensity scores, other unknown or

Full access

Effect of Patient Navigation on Completion of Lung Cancer Screening in Vulnerable Populations

Sheena Bhalla, Vijaya Natchimuthu, Jessica L. Lee, Urooj Wahid, Hong Zhu, Noel O. Santini, Travis Browning, Heidi A. Hamann, David H. Johnson, Hsienchang Chiu, Simon J. Craddock Lee, and David E. Gerber

to prostate-specific antigen testing, Papanicolaou tests, or stool-based colorectal cancer (CRC) screening, LDCT cannot be performed in a clinician’s office or at home. Unlike breast cancer screening, in which coordinated programs may provide

Full access

NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology

Phillip G. Febbo, Marc Ladanyi, Kenneth D. Aldape, Angelo M. De Marzo, M. Elizabeth Hammond, Daniel F. Hayes, A. John Iafrate, R. Kate Kelley, Guido Marcucci, Shuji Ogino, William Pao, Dennis C. Sgroi, and Marian L. Birkeland

Testing in Prostate Cancer Table 9 summarizes current molecular biomarkers in prostate cancer. Prostate-Specific Antigen ( KLK3 ) Prostate-specific antigen (PSA) is a peptidase (gene designation, KLK3 ) found in seminal plasma. Serum levels of

Full access

Quality Measurement in Cancer Care: A Review and Endorsement of High-Impact Measures and Concepts

Thomas A. D’Amico, Lindsey A.M. Bandini, Alan Balch, Al B. Benson III, Stephen B. Edge, C. Lyn Fitzgerald, Robert J. Green, Wui-Jin Koh, Michael Kolodziej, Shaji Kumar, Neal J. Meropol, James L. Mohler, David Pfister, Ronald S. Walters, and Robert W. Carlson

prostate-specific antigen (PSA) level to evaluate oncologic control must be combined with validated instruments for adverse effect measurement to allow patients to evaluate radiation or surgical sequelae, the so-called trifecta. 47 PSA Monitoring PSA level

Full access

NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

Featured Updates to the NCCN Guidelines

Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George Netto, David F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, III, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass

cancer declined, likely in part as a result of decreased detection, attributed to decreased rates of prostate-specific antigen (PSA) screening. 1 After that, incidence rates stabilized and may now be starting to increase as PSA testing is regaining

Full access

New Options for the Management of Castration-Resistant Prostate Cancer: A Case Perspective

Dawn Goetz

, with the chief complaint of rapidly rising prostate-specific antigen (PSA) levels and significant upper back and neck pain. The patient's prostate cancer history dated back to an initial diagnosis in 2007 after he complained to his primary care doctor

Full access

NCCN Guidelines® Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2024

Featured Updates to the NCCN Guidelines

Mary B. Daly, Tuya Pal, Kara N. Maxwell, Jane Churpek, Wendy Kohlmann, Zahraa AlHilli, Banu Arun, Saundra S. Buys, Heather Cheng, Susan M. Domchek, Susan Friedman, Veda Giri, Michael Goggins, Andrea Hagemann, Ashley Hendrix, Mollie L. Hutton, Beth Y. Karlan, Nawal Kassem, Seema Khan, Katia Khoury, Allison W. Kurian, Christine Laronga, Julie S. Mak, John Mansour, Kevin McDonnell, Carolyn S. Menendez, Sofia D. Merajver, Barbara S. Norquist, Kenneth Offit, Dominique Rash, Gwen Reiser, Leigha Senter-Jamieson, Kristen Mahoney Shannon, Kala Visvanathan, Jeanna Welborn, Myra J. Wick, Marie Wood, Matthew B. Yurgelun, Mary A. Dwyer, and Susan D. Darlow

colonoscopy and upper endoscopy every 2 to 5 y starting at age ≤25 years in the context of prior abdominal radiation or family history. Dermatologic examinations are recommended. Finally, prostate cancer screening with prostate-specific antigen testing is